Business Context and Reporting Period
Revelation Biosciences, Inc. (REVB) filed a Form 8-K on August 21, 2024, reporting the entry into a material definitive agreement. The Company, a biopharmaceutical firm developing therapies for kidney injury and infection, executed a warrant exercise inducement offer to raise capital for clinical development.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $3.8 million from the exercise of Existing Warrants and payment for Inducement Warrants, before deducting financial advisory fees.
- Existing Warrants Exercised: 2,548,060 shares at a reduced exercise price of $1.50 per share.
- Inducement Warrants Issued: Up to 5,096,120 shares exercisable at $1.00 per share over a five-year period.
- Transaction Costs: A cash fee of approximately $267,546 was agreed upon for financial advisory services provided by Roth Capital Partners, LLC.
- Use of Proceeds: Funding clinical trials for GEM-AKI, GEM-CKD, and GEM-PSI, including manufacturing clinical batches of Gemini, conducting a Phase 1b study for GEM-AKI in CKD patients, and general working capital.
Material Changes and Adjustments
The filing details a material modification to the rights of security holders regarding warrant exercise terms. The Company reduced the exercise price of Existing Warrants to $1.50 per share to induce immediate exercise. Additionally, pursuant to anti-dilution provisions, the exercise price for Class C and Class D Common Stock Purchase Warrants (covering 7,746 and 80,940 shares, respectively) was adjusted to $1.00 per share.
Outlook, Risks, and Contingencies
Management intends to utilize the net proceeds to advance the clinical development pipeline, specifically targeting the manufacturing of Gemini and the execution of a planned Phase 1b clinical study. The Inducement Warrants were issued in a private placement under Section 4(a)(2) of the Securities Act and are not currently registered. The Company has agreed to file a resale registration statement on Form S-3 within twenty days of closing to register the resale of the Warrant Shares. The transaction was structured as an at-market transaction under Nasdaq rules.
Investor Verification Checklist
- Verify the final net proceeds after deducting the $267,546 advisory fee and other transaction costs.
- Confirm the filing date and effectiveness of the Form S-3 resale registration statement for the Inducement Warrant Shares.
- Monitor the timeline for the Phase 1b clinical study for GEM-AKI in CKD patients as a key milestone for capital utilization.
- Review the dilution impact of the 5,096,120 new Inducement Warrants exercisable at $1.00 per share.